Company intelligence / Profile preview

Polyrizon Ltd.

Ownership: Public · PLRZ
Employees: ~6
Development stage: Preclinical

Overview

Polyrizon is developing innovative medical device hydrogels delivered as nasal sprays that form a protective barrier against allergens and viruses in the nasal cavity. The company is currently in the development stage with products like PL-14 (nasal allergies blocker), PL-15 (COVID-19), and PL-16 (influenza blockers)[2][3][4].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Hydrogel-based nasal sprays
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

PL-14

Pre-clinical

Indications: Nasal allergies

2 more assets in the full pipeline.

Financials

Market cap: $13M
Total revenue: $0
Enterprise value: $-2.1M

Beyond the preview

Go deeper on Polyrizon Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyrizon Ltd..